ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

To join the ELIOS study, you would need to be an adult in Canada, aged 18 to 99, and have been diagnosed with active relapsing-remitting MS. You should be about to start taking a new MS medication called ofatumumab, and the decision to prescribe this medication must have been made by your doctor before you consider joining the study.

You would also need to be able to provide blood samples and understand spoken or written Canadian English or French. Your vision should be good enough, with glasses or contacts if needed, to read instructions on a screen. Your doctor will also check that your physical disability hasn't been steadily getting worse over the last six months, outside of any relapses.

However, you cannot join if you have other types of MS, such as primary progressive MS, or if you have inactive secondary progressive MS. You also wouldn't be able to take part if you have any other health condition that would make it difficult or unsafe to participate in the study.

If you decide to take part in the ELIOS study, you'll be joining a group of patients who are already starting treatment with ofatumumab. You'll have regular visits where researchers will use a special eye-tracking device to measure your eye movements. This device has not yet been approved by health authorities, so this is part of testing how well it works.

Throughout the study, you'll also be asked to provide blood samples. The study will follow your progress and how your MS is changing while you are on your regular treatment. The overall aim is to gather information over time to see if the eye-tracking measurements can help understand how the disease is progressing. The total duration of your involvement in the study would depend on the study plan, but it will involve ongoing assessments and follow-up.